In this week's edition...
— PIPC Report: The UK Health System, Lessons for the U.S. and the Risks of MFN Drug Pricing. Click here to read the full report.
— Former Members of Congress and Physicians Call Out How MFN Devalues Disabled Lives. View the article here.
— Louisiana Advances Bill to Import QALYs, Advocates Respond. View the Bossier Press-Tribune article here. View the PIPC letter here.
— Michigan Seeks to Incorporate QALYs into Appropriations Bill. View the letters HERE.
— MFN Policies Devalue Patients, Limiting Treatments for People like Gerry. We must not import access restrictions that devalue people living with chronic illnesses.
— Access at Risk: Innovation for Health Equity in a Time of Uncertainty. Register here.
— Trump Administration Pushes Compliance Deadlines for DOJ's Title II Rule on Digital Accessibility. PIPC will continue to monitor the rule and advocate to ensure that the disabled community does not witness a deterioration in accessibility standards.
— Patients and People with Disabilities Urge Policymakers to Reject Importing Foreign Drug Pricing Policies. View PIPC’s response to the SOTU here. View the letters from 119 organizations to CMS commenting on the GLOBE and GUARD models here. View the blog here. Learn more about the implications of importing QALYs here.
— HEMA Finalizes Report on Economic Evaluation. View PIPC’s critique of the draft report here. View the final report here.
— Devaluing Disabled Lives, International Laws Fall Short of Protecting Equal Access to Health Care for People with Disabilities as Compared to the U.S. View the new Data Mine Blog here.
— Health Affairs Discusses MFN Drug Pricing and QALYs. Click here to read the full article.
— Opportunity: Sign an Open Letter Rejecting Use of QALYs and Similar Measures. See details below.
— Emerging Threats in States for Use of Discriminatory Metrics. See details below.
— What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below.
— ICER's QALY-Based Study Topics. See details below.
— Upcoming Events and Webinars. See details below.
— PIPC Report: The UK Health System, Lessons for the U.S. and the Risks of MFN Drug Pricing. Click here to read the full report.
— Former Members of Congress and Physicians Call Out How MFN Devalues Disabled Lives. View the article here.
— Louisiana Advances Bill to Import QALYs, Advocates Respond. View the Bossier Press-Tribune article here. View the PIPC letter here.
— Michigan Seeks to Incorporate QALYs into Appropriations Bill. View the letters HERE.
— MFN Policies Devalue Patients, Limiting Treatments for People like Gerry. We must not import access restrictions that devalue people living with chronic illnesses.
— Access at Risk: Innovation for Health Equity in a Time of Uncertainty. Register here.
— Trump Administration Pushes Compliance Deadlines for DOJ's Title II Rule on Digital Accessibility. PIPC will continue to monitor the rule and advocate to ensure that the disabled community does not witness a deterioration in accessibility standards.
— Patients and People with Disabilities Urge Policymakers to Reject Importing Foreign Drug Pricing Policies. View PIPC’s response to the SOTU here. View the letters from 119 organizations to CMS commenting on the GLOBE and GUARD models here. View the blog here. Learn more about the implications of importing QALYs here.
— HEMA Finalizes Report on Economic Evaluation. View PIPC’s critique of the draft report here. View the final report here.
— Devaluing Disabled Lives, International Laws Fall Short of Protecting Equal Access to Health Care for People with Disabilities as Compared to the U.S. View the new Data Mine Blog here.
— Health Affairs Discusses MFN Drug Pricing and QALYs. Click here to read the full article.
— Opportunity: Sign an Open Letter Rejecting Use of QALYs and Similar Measures. See details below.
— Emerging Threats in States for Use of Discriminatory Metrics. See details below.
— What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below.
— ICER's QALY-Based Study Topics. See details below.
— Upcoming Events and Webinars. See details below.
